managing semaglutide side effects The infographic compares 10 commonly discussed weight-loss medicines. Tirzepatide and produce the greatest average loss, but they can cause nausea, vomiting, constipation, gallstones and pancreatitis. Oral semaglutide and orforglipron avoid glp-1 semaglutide side effects Struggling

doi: 10.1021/acsnano.1c10921 115 TangCAngBTPervaizS

Contact your GP or diabetes specialist nurse if you experience: Persistent insomnia lasting more than 23 weeks despite implementing sleep hygiene measures Severe gastrointestinal symptoms that significantly disrupt sleep and daily functioning Symptoms of hypoglycaemia , particularly nocturnal episodes, including night sweats, palpitations, confusion upon waking, or morning headaches Excessive daytime fatigue that interferes with work, driving, or daily activities Mood changes including low mood, anxiety, or irritability that may be related to poor sleep quality Unexplained weight loss exceeding expected therapeutic targets New or worsening visual symptoms , especially if you have existing diabetic retinopathy, as rapid improvement in blood glucose can temporarily worsen retinopathy [14] [15] Seek urgent medical attention if you develop: Signs of severe dehydration from vomiting or diarrhoea (reduced urination, dizziness, confusion), which can lead to acute kidney injury Severe, persistent abdominal pain, particularly if accompanied by vomiting Symptoms of pancreatitis (severe upper abdominal pain radiating to the back) Call 999 for severe hypoglycaemia with confusion, loss of consciousness, or seizures Contact NHS 111 for urgent but non-life-threatening concerns Your healthcare team can assess whether your sleep problems are related to Ozempic or other factors

Read all about it in EyeWorld Weekly To view or add a comment, sign in Innovative Drug Delivery Approaches for GLP-1 Agonists: Enhancing Medication Adherence & Treatment Outcomes: Nasrin Mahmoudi, PharmD, PhD, and Michael Baumann, highlight recent developments in GLP-1 agonist formulations and delivery methods, including advanced injectable formulations, novel oral delivery systems, and topical formulations

Seeds further noted that we are seeing advancement in GLP-1 receptor agonists going from semaglutide (binds with GLP-1 receptors) to tirzepatide (binds with GLP-1 and GIP receptors) to retatrutide (binds with GLP-1, GIP, and glucagon receptors)

Main inclusion criteria included the following: (1) all participants were aged 18 to 70 years

Similar skin changes can occur with any method of rapid weight reduction, whether through dietary modification, increased physical activity, bariatric surgery, or other weight loss medications